miR-130b与碘难治性分化型甲状腺癌的关系研究

Relationship between miR-130b and radioiodian refractory differentiate thyroid carcinoma

目的探讨miR-130b与碘难治性分化型甲状腺癌(RR-DTC)的关系。方法选取2013年1月至2015年12月在我院就诊并行^(131)I照射治疗的远处转移DTC患者104例,随访36个月,根据治疗结果,将患者分为RR-DTC组(41例)和碘治疗有效组(R-DTC组)(63例),检测患者^(131)I照射治疗前肿瘤组织miR-130b的表达水平,观察患者血清甲状腺球蛋白(Tg)的变化趋势及其与miR-130b的相关性。结果①^(131)I照射治疗前,R-DTC组和RR-DTC组患者肿瘤组织中miR-130b水平分别为(0.79±0.10)和(0.43±0.07),RR-DTC组患者miR-130b水平明显低于R-DTC组,而血清Tg水平高于R-DTC组(P<0.05)。治疗后,RR-DTC组患者Tg同比下降率和T/B分别为10.13%±9.87%和4.29%±1.64%,明显低于R-DTC组(P<0.05)。②Spearman相关性分析显示,Tg同比下降率、T/B与miR-130b呈正相关性(r_s=0.928、0.896,P<0.05)。③ROC曲线分析显示,miR-130b诊断RR-DTC的截断值为0.485,曲线下面积为0.662。根据miR-130b的截断值,将RR-DTC组患者分为<0.485亚组(23例)和≥0.485亚组(18例)。④随访期间,<0.485亚组和≥0.485亚组RR-DTC患者3年生存率分别为34.78%、50.0%,经Log-rank检验,差异无统计学意义(P>0.05)。结论甲状腺癌组织miR-130b表达有望成为难治性分化型甲状腺癌潜在的辅助诊断指标之一。

Objective To investigate the relationship between miR-130b and radioiodian refractory differentiate thyroid carcinoma(RR-DTC).Methods Totally 104 DTC patients received 131I therapy from January 2013 to December 2015 in our hospital were selected,and were divided into RR-DTC group and response group(R-DTC)according to the therapeutic results after 36 months of follow-up.The serum levels of miR-130b in tumor tissues were detected before 131I therapy.The relevance between the change of Tg or T/B and miR-130b was analyzed by Spearman analysis.Results ①The expression of miR-130b in R-DTC group and RR-DTC group were(0.79 ± 0.10)and(0.43 ± 0.07)before 131I therapy.The expression of miR-130b in RR-DTC group was lower than that in R-DTC group,while the Tg levels were higher than those in R-DTC group before 131I therapy(P<0.05).The week-to-week reduction rate of Tg and T/B in RR-DTC group were 10.13%± 9.87% and 4.29%± 1.64%,which were lower than those of RDTC group after 131I therapy(P<0.05).②The Spearman analysis showed the changes of Tg and T/B were positively correlated with miR-130b(rs=0.928,rs=0.896,P<0.05).③ROC curve showed that the cutoff point of miR-130b was 0.485,and the AUC was 0.662.The patients were divided into two groups according to the cutoff point:there were 23 RR-DTC patients in<0.485 group and 15 patients in ≥0.485 group.④After the follow-up,the 3-year survival rates of patients in<0.485 group and ≥0.485 group were 34.78% and 50.0%,respitively,and there was no significant difference between the two groups by Log-rank analysis(P>0.05).Conclusion It's suggested that miR-130b could be a potential predictor for radioiodian refractory differentiate thyroid carcinoma.